R&D Pipeline (As of April 2017)

*Compounds with "In-house" in this column include ones discovered by collaborative research.

AGS67E Lymphoid malignancies P-I Injection In-house (ADC technology in-licensed from Seattle Genetics) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)

R&D Pipeline (As of July 2016) 1. Global Development Underlined items indicate for changes from the previous announcement on May 11, (1) Regulat

R&D Pipeline (As of July 2016) 1. Global Development Underlined items indicate for changes from the previous announcement on May 11, 2016. (1) Regulatory decision *Compounds with "" in this column include

R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018.

R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Castration-resistant prostate

R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018.

R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018. Oncology (1/2) MDV3100 enzalutamide (XTANDI ) Androgen receptor inhibitor Non-metastatic

R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, 2018.

R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, 2018. Oncology (1/2) enzalutamide MDV3100 (XTANDI ) Androgen receptor inhibitor Non-metastatic

R&D Pipeline (May 2014) 1. Global Development (1) Approved Product Name (Approval Date) Classification Target Disease Area * MDV3100 enzalutamide XTAN

R&D Pipeline (May 2014) 1. Global Development (1) Approved Product Name (Approval Date) Classification Target Disease Area * MDV3100 enzalutamide XTANDI (Mar. 2014) Androgen receptor inhibitor

(2) Phase-lll / Phase-ll (2/3) ASP7487 (OSI-906) linsitinib IGF-1R/IR tyrosine kinase inhibitor Adrenocortical carcinoma Ovarian cancer, Non-small cel

R&D Pipeline (February 2012) 1. Global Development (1) Filed YM178 mirabegron Beta 3 receptor agonist Overactive bladder associated with symptoms of urgency, urinary frequency, and urge urinary incontinece

(3) Phase-lll / Phase-ll (1/3) Stage in the most advanced territory EC905 solifenacin/ tamsulosin Concomitant use of solifenacin and tamsulosin Lower

R&D Pipeline (November 2011) 1. Global Development (1) Approved telavancin Product Name (Approval Date) VIBATIV (Sep. 2011) Classification Lipoglycopeptide antibiotic Therapeutic Target Treatment of adults

R&D Pipeline (May 2010)

R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication

R&D Pipeline (May 2006)

R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence

Q3/FY2016 FINANCIAL RESULTS

Q3/FY2016 FINANCIAL RESULTS ENDED DECEMBER 31, 2016 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. January 31, 2017 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING

R&D Pipeline (November 2006)

R&D Pipeline (November 2006) 1Japan (1)Filed Code No Generic Name (Filing Date ) Therapeutic Target Classification YM177 celecoxib (Dec 2002) Rheumatoid arthritis, osteoarthritis, low back pain, etc Cyclooxygenase-II

R&D Pipeline (November 2005)

R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)

Q3/FY2017 FINANCIAL RESULTS

Q3/FY2017 FINANCIAL RESULTS ENDED DECEMBER 31, 2017 Chikashi Takeda Chief Financial Officer Astellas Pharma Inc. January 31, 2018 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION 2 In this material,

Q1/FY2016 FINANCIAL RESULTS

Q1/FY2016 FINANCIAL RESULTS ENDED JUNE 30, 2016 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. July 29, 2016 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status

Maximizing the Product Value

Business Review Review of Operations by Therapeutic Area Astellas is working to steadily grow and maximize the value of products developed through its investments over the years, including its growth drivers

2Q/FY2015 Financial Results

2Q/FY2015 Financial Results Ended September 30, 2015 October 30, 2015 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 0 Cautionary Statement Regarding Forward-Looking Information This material

DEVELOPMENT R&D MEETING Sef Kurstjens, M.D., Ph.D. Chief Medical Officer Astellas Pharma, Inc. December 8, 2016

DEVELOPMENT R&D MEETING 2016 Sef Kurstjens, M.D., Ph.D. Chief Medical Officer Astellas Pharma, Inc. December 8, 2016 DEVELOPMENT PURPOSE 2 Turn innovative science into value for patients by characterizing

Q2/FY2018 FINANCIAL RESULTS

Q2/FY2018 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2018 Kenji Yasukawa, Ph.D President and CEO Astellas Pharma Inc. October 31, 2018 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION 2 In this material,

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status

Financial Results for 1Q/FY2015

Financial Results for 1Q/FY2015 Ending March 31, 2016 July 31, 2015 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. 0 Cautionary Statement Regarding Forward-Looking

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed

Financial Results for FY2014 Ended March 31, 2015

0 Financial Results for FY2014 Ended March 31, 2015 May 11, 2015 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 1 Cautionary Statement Regarding Forward-Looking Information This material includes

Summary of Strategic Competitive Analysis and Publication Planning

Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing

ONO PHARMACEUTICAL CO., LTD.

ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005

ICD-9-CM CODING FUNDAMENTALS CODING EXERCISES

Steps to Accurate Coding Underline the main term, then locate code: Stenosis of Carotid Artery Transient Ischemic Attack Gastrointestinal hemorrhage Degenerative Joint Disease Coronary Artery Disease Alcoholic

Pfizer Pipeline. August 9, 2012

Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information

Overview of Product Pipeline

Overview of Product Pipeline November 4, 2004 Yamanouchi Pharmaceutical Co., Ltd. Shinji Usuda,, Ph. D. Corporate Vice President Director of Drug Development Division Cautionary statement regarding forward-looking

Pfizer Pipeline. November 8, 2012

Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information

ONO PHARMACEUTICAL CO., LTD.

ONO PHARMACEUTICAL CO., LTD. February 6, 2006 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2006

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016

Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive

3Q/FY2015 Financial Results

3Q/FY2015 Financial Results Ended December 31, 2015 January 29, 2016 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. Copyright 2015 Astellas Pharma Inc. 0 Cautionary

How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all

Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We

Pfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals

In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be Yes : Does the activity align with Pfizer s Primary Areas of Interest? (listed

2015 PQRS Registry. Source Measure Title Measure Description CITIUS1

1 CQ-IQ covers 65 CMS defined measures that Eligible Providers (EPs) have to report on to assess quality of care provided to the patients. Version Supported: PQRS Registry 2015 65 measures Reporting Period:

Pharmacotherapy Handbook

Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College

79 HCCs CMS-HCC Risk Adjustment Model. ICD-10-CM to CMS-HCC Crosswalk. Over 9,500 ICD-10-CM codes map to one or more.

2017 CMS-HCC Risk Adjustment Model Over 9,500 ICD-10-CM codes map to one or more 79 HCCs ICD-10-CM to CMS-HCC Crosswalk CMS-HCC Model On April 4, 2016, the Centers for Medicare & Medicaid Services (CMS)

Financial Results for FY2013 Ended March 31, May 12, 2014 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc.

0 Financial Results for Ended March 31, 2014 May 12, 2014 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 1 Cautionary Statement Regarding Forward-Looking Information This material includes forward-looking

CUMULATIVE ILLNESS RATING SCALE (CIRS)

CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the

Consolidated Financial Forecast for the Year Ending March 31,2014 Year ending March 31,2014 Net sales 148,300 $ 1,412,381 Operating income 27, ,

ONO PHARMACEUTICAL CO., LTD. February 4, 2014 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31, 2013. This First - Third Quarter Flash Report

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

Merck Pipeline. August 1, 2018

Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate

Third Quarter Consolidated Financial Results

Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2014 1. Overview of consolidated results 2. Highlights of Business Performance 3. Actual and Forecast of Main Subsidiary

Summary of late stage clinical trials. As of Jun. 30, 2018

Summary of late stage clinical trials As of Jun. 30, 2018 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously

CHRONIC TREATMENT GUIDELINES

CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic

Premium Specialty: Pediatrics

Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of

Development pipeline (as of January 31, 2019)

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2018 (IFRS) 14 Development pipeline (as of January 31, 2019) Oncology GA101 / RG7159 Follicular lymphoma

Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.

Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female

Development pipeline (as of February 1, 2017)

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2016 (IFRS) 13 Development pipeline (as of February 1, 2017) Oncology Additional indication name

Development status of OPDIVO (nivolumab) 1

November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell

ALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

FOR IMMEDIATE RELEASE Ironwood Contact: Almirall Contact: Susan Brady Ketchum Pleon Corporate Communications Amanda Sefton 617.621.8304 +44 (0) 207.611.3653 sbrady@ironwoodpharma.com amanda.sefton@ketchumpleon.com

Merck Pipeline. November 1, 2017

Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such

Major R&D Pipeline As of January 2016

Major R&D Pipeline As of January 2016 Therapeutic area Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application DS-1040 (Acute ischemic stroke / TAFIa DS-2330 (Hyperphosphatemia) DS-9231/TS23 (Thrombosis

Development Pipeline Progress Status. February 1, 2019

Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)

David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803

David Henry Jablonski, M.D. 1812 North Mills Avenue Orlando, FL 32803 EDUCATION: University of Florida College of Medicine, Gainesville, Florida Division of Urology Residency Training Program July 1994-June

Summary of late-stage clinical trials. As of Dec. 31, 2017

Summary of late-stage clinical trials As of Dec. 31, 2017 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously

DELAYED DIAGNOSIS. Mean time to diagnosis = 4-7 years Mean # of physicians = 8 NIDDK criteria underdiagnoses >60%

DELAYED DIAGNOSIS Mean time to diagnosis = 4-7 years Mean # of physicians = 8 NIDDK criteria underdiagnoses >6% 1 PREVALENCE 1,, 9,, 8,, 7,, 6,, 5,, 4,, 3,, 2,, 1,, NHS "Prostatitis" "Endometriosis" The

Pfizer Pipeline. May 10, 2012

Pfizer Pipeline May 10, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information

Internal Medicine Certification Examination Blueprint

Internal Medicine Certification Examination Blueprint What Does the Examination Cover? The exam is designed to evaluate the extent of the candidate s knowledge and clinical judgment in the areas in which

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes

Pfizer Pipeline. February 28, 2012

Pfizer Pipeline February 28, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)

Developmental Therapeutics for Genitourinary Malignancies

Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019

January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest

Financial Results for the 2Q/FY 2009 Ending March 31, November 6, 2009 Masafumi Nogimori President and CEO Astellas Pharma Inc.

Financial Results for the 2Q/FY 2009 Ending March 31, 2010 November 6, 2009 Masafumi Nogimori President and CEO Astellas Pharma Inc. Cautionary Statement Regarding Forward-Looking Information This material

OCHSNER PHYSICIAN PARTNERS. PQRS Measures by Specialty (FINAL)

OCHSNER PHYSICIAN PARTNERS PQRS Measures by Specialty (FINAL) Allergy and Immunology 2. Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting (PQRS 53) 3. Patients aged 18 years

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths

RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected

Summary of late stage clinical trials. As of Jun. 30, 2017

Summary of late stage clinical trials As of Jun. 30, 2017 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously

What is on the Horizon in Drug Therapy for OAB?

What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures

Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL 32803

Jeffrey Richard Thill, M.D. 1812 North Mills Avenue Orlando, FL 32803 CURRENT POSITION AFFILIATIONS BIRTHPLACE BOARD CERTIFIED UROLOGIST WINTER PARK UROLOGY ASSOCIATES, P.A. 1812 NORTH MILLS AVENUE, ORLANDO,

Profile of Respondents Phase 1 F2F Focus Group 1

Profile of Respondents Phase 1 F2F Focus Group 1 Name M/F Gender demographic classification Diagnosed with long term chronic healthcare Chronic healthcare minutes of physical activity a week Attitudinal

PHARMACY TIMES BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT August 23, 2012

PHARMACY TIMES BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT August 23, 2012 We would like to inform you of the following changes to the 2012 IEHP Formulary that were approved by the Pharmacy and Therapeutics

Overactive Bladder Syndrome

Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive

Intensity: 0-10 (10 is the worse pain you have ever experienced in your life that you would want to jump from a building, 0 is no pain)

Patient Questionnaire: Name: Date: Occupation: Date of Birth: Age: Sex: Male Female Referring Physician: Chief Complaint: Describe your Pain: sudden onset gradual constant intermittent worsening improving

Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018

Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply

CONTENT OUTLINE FOR THE PHARMACOTHERAPY CERTIFICATION EXAMINATION

CONTENT OUTLINE FOR THE PHARMACOTHERAPY CERTIFICATION EXAMINATION The following domains, tasks and knowledge statements were delineated by the BPS Specialty Council on Pharmacotherapy and validated through

Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy

Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) Results Confirm and Extend 40-Week Findings that

Contents. copyrighted material by PRO-ED, Inc. Chapter 1. Chapter 2. Chapter 3. Chapter 4. Chapter 5. Conditions in Athletic Injuries

Acknowledgments xiii Introduction to the First Edition xv Introduction to the Second Edition xvii Chapter 1 Conditions in Athletic Injuries Anterior Cruciate Ligament (ACL) Tear 2 Biceps Tendon Strain

North of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday

UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty

UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty 666700 Acne Family Medicine, Internal Medicine, Pediatrics 438300 Acute Bronchitis Allergy,

CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER

RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.

New Mexico Health Connections Drug Safety Updates Q4 2018

Dupixent dupilumab Moderate-to-severe atopic dermatitis, Moderate-to-Severe asthma SQ Injection On October 19, 2018, new warnings were added to the Dupixent drug label regarding judicious use in eosinophilic

Development status of OPDIVO (nivolumab) 1

August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018

January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia

Table of Contents. Course CME Credits. General Principles Topic CME Credit(s)

Table of Contents Course Course CME Credits Med-Challenger SPEX Comprehensive Review 266.0 CME Credits General Principles 21.0 CME Credit(s) Abdominal Pain 1.0 Acute Pelvic Pain in Women 1.0 Acute Vaginal

Primary Care management of Overactive Bladder (OAB)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up

Dr. Melissa Kagarise, PA C

Dr. Melissa Kagarise, PA C This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of

Various Types. Ralph Boling, DO, FACOG

Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with

Partnering Activity Update

Partnering Activity Update February 2, 2018 Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2010 KYPROLIS / Carfilzomib Multiple Myeloma / Proteasome inhibitor

About X-Linked Hypophosphatemia (XLH)

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal

New Merck Pipeline. Combined Legacy Merck and Schering-Plough Research Pipelines

New Merck Pipeline Combined Legacy Merck and Schering-Plough Research Pipelines November 4, 2009 Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined

Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC

Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,

Genentech Research & Early Development

Genentech Research & Early Development Founders Research Centers 1 & 2 Founders Research Centers 1 & 2 Andrew Chan, M.D., Ph.D. Senior Vice President, Research Biology September 2017 gred focus areas Discovering

NON-Neurogenic Chronic Urinary Retention AUA White Paper

NON-Neurogenic Chronic Urinary Retention AUA White Paper Great Lakes SUNA Inside Urology March 16, 2018 Michelle J. Lajiness FNP-BC Nurse Practitioner DMC Urology Incidence Really unknown Lack consensus